BUDGET IMPACT ANALYSIS OF INTRODUCTION OF RITUXIMAB BIOSIMILAR IN THE UNITED STATES FROM A PAYER PERSPECTIVE

被引：0
|
作者：
Ektare, V [1 ]
Liu, R. [2 ]
Stephens, J. [2 ]
Al Taie, A. [3 ]
Shelbaya, A. [3 ,4 ]
机构：
[1] Pharmerit India Private Ltd, Mumbai, Maharashtra, India
[2] Pharmerit Int, Bethesda, MD USA
[3] Pfizer Inc, New York, NY USA
[4] Columbia Univ, Mailman Sch Publ Hlth, New York, NY 10027 USA
来源：
VALUE IN HEALTH | 2020年 / 23卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PBI17
引用
收藏
页码：S16 / S17
页数：2
相关论文
共 50 条
  • [1] BUDGET IMPACT ANALYSIS OF INTRODUCTION OF BEVACIZUMAB BIOSIMILAR IN THE UNITED STATES FROM A PAYER PERSPECTIVE
    Ektare, V
    Liu, R.
    Stephens, J.
    Shelbaya, A.
    Yang, J.
    VALUE IN HEALTH, 2020, 23 : S15 - S15
  • [2] Budget impact analysis of including biosimilar adalimumab on formulary: A United States payer perspective
    Chaplin, Stephen
    van Stiphout, Joris
    Chen, Anna
    Li, Edward
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2024, 30 (11): : 1226 - 1238
  • [3] Budget impact analysis of rituximab biosimilar in Italy from the hospital and payer perspectives
    Rognoni, Carla
    Bertolani, Arianna
    Jommi, Claudio
    GLOBAL & REGIONAL HEALTH TECHNOLOGY ASSESSMENT, 2018,
  • [4] BUDGET IMPACT ANALYSIS OF INTRODUCTION OF SUBCUTANEOUS INFLIXIMAB IN FRANCE FROM A PAYER PERSPECTIVE
    Pradie, M.
    Hadjadj, C.
    Moreau, Petiteau F.
    VALUE IN HEALTH, 2022, 25 (01) : S81 - S81
  • [5] BUDGET IMPACT ANALYSIS OF INTRODUCING FRUQUINTINIB FOR THE TREATMENT OF PREVIOUSLY TREATED METASTATIC COLORECTAL CANCER IN THE UNITED STATES FROM THE PAYER PERSPECTIVE
    Hernandez, L. G.
    Paly, V
    Li, S.
    Khanduri, P.
    Asfaw, A. A.
    Zou, D.
    VALUE IN HEALTH, 2024, 27 (06) : S106 - S106
  • [6] BUDGET IMPACT OF ZANUBRUTINIB TO TREAT RELAPSED OR REFRACTORY MARGINAL ZONE LYMPHOMA FROM A PAYER PERSPECTIVE IN THE UNITED STATES
    Liu, S.
    Yang, K.
    Carter, J.
    Zimmerman, T.
    Tang, B.
    VALUE IN HEALTH, 2022, 25 (01) : S62 - S62
  • [7] Introduction of Biosimilar Rituximab: A Hospital Perspective
    Cheesman, Simon
    HEMASPHERE, 2021, 5 (01): : E515
  • [8] Patient-Administered Biologic and Biosimilar Filgrastim May Offer More Affordable Options for Patients with Nonmyeloid Malignancies Receiving Chemotherapy in the United States: A Budget Impact Analysis from the Payer Perspective
    Trautman, Holly
    Szabo, Erika
    James, Elizabeth
    Tang, Boxiong
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2019, 25 (01): : 94 - 101
  • [9] INTRODUCTION OF A LOW-DOSE LEVONORGESTREL INTRAUTERINE CONTRACEPTIVE SYSTEM: A THREE-YEAR BUDGET IMPACT ANALYSIS FROM A THIRD-PARTY PAYER PERSPECTIVE IN THE UNITED STATES
    Trussell, J.
    Ferrufino, C. P.
    Hawes, C.
    Pocoski, J.
    Filonenko, A.
    Kim, R. S.
    McCoy, M. A.
    Law, A. W.
    VALUE IN HEALTH, 2013, 16 (03) : A71 - A72
  • [10] Bariatric Surgery Coverage: a Comprehensive Budget Impact Analysis from a Payer Perspective
    Swetha R. Palli
    John A. Rizzo
    Natalie Heidrich
    Obesity Surgery, 2018, 28 : 1711 - 1723
12345